Ulka Vaishampayan, MD, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib plus nivolumab as treatment of patients with metastatic renal cell carcinoma compared with sunitinib.
Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the findings from the phase 3 CheckMate-9ER study, which demonstrated promising response and survival outcomes with the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) as treatment of patients with metastatic renal cell carcinoma (mRCC) compared with sunitinib (Sutent).
Overall, the frontline treatment of cabozantinib plus nivolumab improved efficacy compared with sunitinib in patients with newly diagnosed mRCC, Vaishampayan says. The response rate in this study was doubled, and the progression-free survival (PFS) was statistically and significantly improved with the combination over sunitinib. The median PFS with the combination was 16.6 months compared with 8.3 months in the control arm (HR, 0.51; P <.0001).
The overall response rate with the combination 55.7% versus 27.1% with sunitinib, and completes responses were observed in 8.0%, partial responses in 47.7%, and stable disease in 32.2% of patients in the combination arm of the study. The safety profile for the combination of nivolumab and cabozantinib appears manageable as treatment of patients with mRCC.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes
September 30th 2024Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.
Read More